Abstract: The present invention relates to: a biomarker composition for predicting the prognosis of brain disease caused by microplastic exposure; and a use thereof. More particularly, it was confirmed that polyethylene microspheres (PS) in a mouse animal model orally administered with the PS penetrate brain tissue to change the level of metabolites inside the brain tissue and the diversity of intestinal microorganisms, thereby causing brain disease, and thus the present invention is intended to provide a biomarker composition for predicting the prognosis of brain disease caused by microplastic exposure, and a method for predicting the prognosis of brain disease using same.

Abstract: An organic formulation based on a mixture of microorganisms and other derived organic components, obtained from plants that inhabit different extreme environments, including the Chilean Antarctic territory, for protecting plants and agricultural crops against environmental conditions, especially with respect to cold stress, water stress, and plant infection by pests and insects, is provided. Due to the activity of the consortia of microorganisms that compose it and its derived components, it favours plant growth and reduces the damage associated with cold and water stress in agricultural crops.

Abstract: The present invention relates to the strain Phascolarctobacterium faecium DSM 32890 and to its use for the regulation of appetite and the treatment and/or prevention of overweight or the associated metabolic and immunological changes, specifically, hyperglycaemia, glucose intolerance, insulin resistance, dyslipidemia (hypertriglyceridemia, hypercholesterolemia), metabolic syndrome, diabetes and intestinal and/or peripheral tissue inflammation.

Abstract: Described herein are methods for treating radicular pain due to radiculopathies comprising administering a therapeutically effective amount of a composition comprising cell-free amniotic fluid.

Abstract: The present invention relates to a composition comprising bacteria of the Delftia genus, specifically a composition comprising Delftia tsuruhatensis as well as the bacteria itself for use in the prevention of malaria transmission and methods of using the compositions for reducing malaria and/or malaria parasite transmission.

Abstract: Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.

Abstract: An object of the present invention is to provide a composition for promoting sleep, that enables an increase of the sleep amounts in the overall night and in the initial stage of the night, a decrease of the sleep onset latent time, and an increase of the length of a sleep episode, and that is excellent in the stability and the safety. Another object of the present invention is to provide a food, a drug, and a feed that each include the composition for promoting sleep. The composition for promoting sleep is characterized in that the composition for promoting sleep includes a microorganism belonging to either Bifidobacterium adolescentis or Lactobacillus plantarum, or a culture thereof as an active ingredient.

Abstract: Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

Abstract: The present invention addresses the problem of providing an effective new means for efficiently reducing the amount of diacylglycerol in a fat/oil (by conversion into triacylglycerol). Disclosed is a method for producing a fat/oil, including a step in which a lipase having a ratio of transesterification activity to hydrolysis activity of 0.007 or higher is caused to act on a diacylglycerol-containing fat/oil.

Abstract: Methods of inhibiting growth of cells or tissue of a primary and/or secondary tumor, and/or of stimulating an immunological response to the tumor, in a subject in need thereof, and systems for performing same, are provided. The methods employ local administration of a gas, such as gaseous nitric oxide, typically at a high dose. Immune cells obtained upon treating a tumor with gaseous nitric oxide, either in vivo or ex vivo, and methods employing same are also provided.

Abstract: The present disclosure provides solutions to various challenges in health, including health challenges related to high consumption of carbohydrate and/or low consumption of soluble fiber. The present disclosure provides, among other things, bacteria engineered for expression of a fiber-synthesizing enzyme, e.g., for expression of the enzyme in the gut (e.g., in the intestine). In particular embodiments, the present disclosure provides bacteria engineered for expression of a fiber-synthesizing enzyme that consumes carbohydrate in the process of synthesizing fiber, e.g., in the gut. The present disclosure further includes formulations of isolated fiber-synthesizing enzymes for administration to subjects.

Abstract: A method of obtaining cell derived vesicles comprising an active wild-type p53 is disclosed. The method comprising: (i) isolating cell derived vesicles from a biological sample comprising cells; and (ii) treating the cell derived vesicles with a DNA damaging agent, or the method comprising: (i) treating cells with a DNA damaging agent; and (ii) isolating cell derived vesicles from a biological sample comprising the cells. A proteinaceous preparation comprising cell derived vesicles and a pharmaceutical composition comprising the proteinaceous preparation are also disclosed. Methods of treating a disease, disorder or condition associated with a mutant or a nonfunctional p53 protein and methods of inducing apoptosis of a target cell comprising a mutant or a nonfunctional p53 protein are also disclosed.

Abstract: Methods and products for treating capsular contractures of breast implants including (1) platelet-rich fibrin (PRF) fraction from a patient who exhibits capsular contracture of a breast implant; and (2) applying the PRF fraction to said capsular contracture, thereby relaxing the capsular contracture.

Abstract: According to the invention, a novel Bifidobacterial strain having an ability of assimilating two or more kinds of HMO is provided. The strain is selected from the group consisting of Bifidobacterium longum subspecies infantis (NITE BP-03068), Bifidobacterium bifidum (NITE BP-03058) and Bifidobacterium bifidum (NITE BP-03067).

Abstract: Novel strains of Lactobacillus plantarum GCWB1001 deposited as accession number KCCM12698P, Pediococcus acidilactici GCWB1085 deposited as accession number KCCM12699P, or Lactobacillus rhamnosus GCWB1156 deposited as accession number KCCM12700P are disclosed. The novel strains have the excellent effect of treating or alleviating respiratory diseases. Additionally, provided are a pharmaceutical composition, a health functional food composition, and probiotics, all of which have the effect of treating or alleviating inflammatory diseases or respiratory diseases, containing any one of the novel strains.

Abstract: The present invention provides for compositions and methods for treating colorectal cancer or for reducing the risk of developing the disease in an individual. More specifically, compositions comprising an effective amount of beneficial bacteria such as Lactobacillus gallinarum, Lactococcus lactis, and Carnobacterium maltaromaticum are provided for the purpose of treating colorectal cancer in a person or for the purpose of reducing a person's risk of later developing colorectal cancer. Corresponding kits and methods are also provided.

Abstract: The disclosure discloses Lactobacillus sp. BB1 enhancing memory ability, a fermented food and application thereof, and belongs to the technical field of microorganisms. The Lactobacillus sp. BB1 disclosed by the disclosure can be used for preparing functional foods, health-care products and drugs that enhance the memory ability of a healthy individual and improve memory impairment. The disclosure further provides the fermented food. The fermented food is prepared by fermentation with Lactobacillus sp. BB1, comprises a solid food, a liquid food and a semisolid food, and has a wide application prospect.

Abstract: Disclosed herein are compositions of biodegradable scaffolds combined with mesenchymal stem cells and methods of use thereof for the regeneration of cranial sutures and treatment of craniosynostosis, which can help reverse increased intracranial pressure and skull and neurocognitive abnormalities.

Abstract: Provided herein are modified Archaeal family B polymerases derived from the Archaeal microorganism Pyrococcus-abyssi that exhibit improved incorporation of nucleotide analogues utilized in DNA sequencing.

Abstract: The disclosure relates generally to a system, device, and method for cell culturing. In certain embodiments, the system, device, and method may be used to encapsulate single cells in embryo-like, core-shell microcapsules. In some embodiments, microfluidic devices may be utilized to fabricate core-shell hydrogel microcapsules, which may be used to encapsulate individual cells. In some embodiments, the disclosed system and method are utilized to encapsulate cancer stem cells. The disclosed system, device, and method can be used to isolate and culture CSCs, to facilitate the understanding of cancer biology and etiology, and to advance the development of effective CSC-targeted cancer therapies.